Market Alert: Trump-Xi APEC Summit a Critical Test for Global Trade Stability
HeraMED Limited (ASX: HMD) has announced a major acceleration of its next-generation AI-driven roadmap, with a focus on enhancing digital maternity care and women’s health. The company is fast-tracking the launch of its AI Clinician Assistant, with the first release expected in Q4 2025, starting with automated documentation and workflow support. Complementing this, HeraMED is developing an ambient scribing tool to streamline consultation note-taking, reducing clinician workload and improving integration with electronic medical records. The company has also initiated a predictive AI maternity care program with RMIT and Digital Health CRC to address high-risk pregnancies among culturally and linguistically diverse (CALD) women, with proof-of-concept models expected in 2026.
Additional innovations include a women’s health AI Virtual Companion to strengthen patient engagement, enhanced interoperability with leading EMR/EHR systems, and expanded integration with both Bluetooth and cellular-based remote monitoring devices. Customer-led upgrades to the AI-powered HeraCARE dashboard will further improve workflow efficiency and clinical insights, strengthening scalability and global adoption.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Oct 31, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
